Clinical trial
High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII…
NCT00447356 · Hackensack Meridian Health, Other · Withdrawn
Key facts
| NCT number | NCT00447356 |
|---|---|
| Title | High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma |
| Official title | Phase III Randomized Study of Four Weeks High Dose IFN-2b in StageT3-T4 or N1 (Microscopic) Melanoma |
| Lead sponsor | Hackensack Meridian Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | recombinant interferon alfa |
| Enrollment | 0 |
| Start date | Jan 1, 2000 |
| First posted | Mar 14, 2007 |
| Last update posted | May 13, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: